FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Manufacturer

Country

Registration Date 30 Aug 2022
Revision Date 30 Aug 2022
Share

Plegridy

(0)

Medicine Pharmaceuticals

Antineoplastic interferons

Drug Information

Generic
Peginterferon beta-1a
Drug Class
Interferons
Therapeutic Class
Immunomodulator
Dosage form
Solution
Route of Administration
SUBCUTANEOUS
Therapeutic Area
1.Relapsing Remitting Multiple Sclerosis

Nanomaterials

Manufacturer Asserted

Polymeric Nanoparticle

Nanoparticle /Nanopowder

Benefit

Plegridy contains the active substance PEG-IFN-β-1a, which is a PEG conjugated form of glycosylated, recombinant IFN-β modified with a single, linear molecule of 20 kDa methoxy-PEG-O-2-methylpropionaldehyde (mPEG). Plegridy or PEG-IFN-β-1a was approved by FDA in 2014 for treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients. Elevations of hepatic enzymes and liver injury have been observed with the use of plegridy. Patients should be checked for signs of hepatic damage and treatment should be stopped if icterus or other clinical symptoms of hepatic dysfunction appears.